Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Yoshiko Urata(Miyoshi Kasei (Japan)), Yoichi Nakanishi(RIKEN Center for Integrative Medical Sciences), Haruyasu Murakami(Shizuoka Cancer Center), Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Hiroshige Yoshioka(Harbin Medical University), Naoyuki Nogami(Hospital Universitario Insular de Gran Canaria), Fumio Imamura(Osaka International Cancer Institute), Tetsuya Oguri(Miyoshi Kasei (Japan)), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Isao Goto, Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Daichi Fujimoto(Hyogo University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Hideo Saka(Nagoya Medical Center), Satoshi Morita(Kyoto University), Nobuyuki Katakami(Takarazuka City Hospital), Yasuo Iwamoto(Hiroshima City Asa Citizens Hospital), Norihiko Ikeda(Tokyo Medical University), Shunichi Negoro(Shikoku Cancer Center), Reiko Kaji(Miyoshi Kasei (Japan)), Masashi Kanehara(Miyoshi Kasei (Japan))
Cited by 160
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k